An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface
- PMID: 32735080
- DOI: 10.1002/med.21716
An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface
Abstract
Preclinical animal studies provide valuable opportunities to better understand human diseases and contribute to major advances in medicine. This review provides a comprehensive overview of ocular parameters in humans and selected animals, with a focus on the ocular surface, detailing species differences in ocular surface anatomy, physiology, tear film dynamics and tear film composition. We describe major pitfalls that tremendously limit the translational potential of traditional laboratory animals (i.e., rabbits, mice, and rats) in ophthalmic research, and highlight the benefits of integrating companion dogs with clinical analogues to human diseases into preclinical pharmacology studies. This One Health approach can help accelerate and improve the framework in which ophthalmic research is translated to the human clinic. Studies can be conducted in canine subjects with naturally occurring or noninvasively induced ocular surface disorders (e.g., dry eye disease, conjunctivitis), reviewed herein, and tear fluid can be easily retrieved from canine eyes for various bioanalytical purposes. In this review, we discuss common tear collection methods, including capillary tubes and Schirmer tear strips, and provide guidelines for tear sampling and extraction to improve the reliability of analyte quantification (drugs, proteins, others).
Keywords: albumin; animal models; ocular surface; one health; pharmacology; tear film; translational research.
© 2020 Wiley Periodicals LLC.
References
REFERENCES
-
- Shah M, Cabrera-Ghayouri S, Christie LA, Held KS, Viswanath V. Translational preclinical pharmacologic disease models for ophthalmic drug development. Pharm Res. 2019;36:58.
-
- Maurice D. The effect of the low blink rate in rabbits on topical drug penetration. J Ocul Pharmacol Ther. 1995;11:297-304.
-
- Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44:409-415.
-
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51.
-
- Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discovery. 2016;15:817-818.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
